Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health Organization pharmacovigilance database-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of sugammadex for reversal of neuromuscular block: A postmarketing study based on the World Health Organization pharmacovigilance database

Published:2022-06-08 Issue:2 Volume:89 Page:449-457
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Lyu Qiang¹²^ORCID,Ye Pei³,Zhang Hewei⁴,Ye Xiaofei⁴,Zheng Yi⁴^ORCID,Xu Jinfang⁴,Chen Xiao⁴^ORCID,Chen Chenxin⁴,Guo Xiaojing⁴

Affiliation:

1. Basic Medical College Naval Medical University Shanghai China

2. 92608 Militang Hospital of PLA Shanghai China

3. Department of Anaesthesiology Huadong Hospital Affiliated to Fudan University Shanghai China

4. Department of Health Statistics, Faculty of Health Service Naval Medical University Shanghai China

Funder

National Natural Science Foundation of China

World Health Organization

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15417

Reference29 articles.

1. Incidence of postoperative residual neuromuscular blockade after general anesthesia: a prospective, multicenter, anesthetist-blind, observational study

2. Reversal of residual neuromuscular block: complications associated with perioperative management of muscle relaxation

3. Sugammadex: the sting in the tail?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pharmacovigilance study of FDA adverse events for sugammadex;Journal of Clinical Anesthesia;2024-10

2. Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block;British Journal of Anaesthesia;2024-01

3. Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase);Expert Opinion on Drug Safety;2023-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3